The University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School at Camden, Cooper Hospital/University Medical Center, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Camden, New Jersey, USA.
Anticancer Res. 2010 Feb;30(2):623-8.
Mifepristone has been demonstrated to improve longevity and quality of life in mice with spontaneous murine cancer without progesterone receptors and in human colon cancer. The present study evaluated the palliative effect of mifepristone in a variety of different types of human cancer.
Mifepristone was given at 200 mg daily orally with permission from the Food and Drug Administration to people with widely metastatic human cancer no longer responsive to other chemotherapy regimens.
Improvement in pain and energy and/or length of life was found in thymic epithelial cell carcinoma, transitional cell carcinoma of the renal pelvis, leiomyosarcoma, pancreatic carcinoma, malignant fibrous histiocytoma and another case of adenocarcinoma of the colon.
Our data demonstrate a palliative role for the use of mifepristone in cancer therapy. Progesterone receptor antagonists should be given a therapeutic trial in larger controlled studies of various malignancies in humans.
米非司酮已被证明可提高无孕激素受体的自发性鼠类癌症和人类结肠癌小鼠的寿命和生活质量。本研究评估了米非司酮在多种不同类型人类癌症中的姑息治疗效果。
经食品和药物管理局批准，给予 200 毫克米非司酮，每日口服，用于广泛转移性人类癌症且对其他化疗方案无反应的患者。
在胸腺癌、肾盂移行细胞癌、平滑肌肉瘤、胰腺癌、恶性纤维组织细胞瘤和另 1 例结肠癌腺癌中发现疼痛、体力和/或寿命得到改善。
我们的数据表明，米非司酮在癌症治疗中具有姑息作用。孕激素受体拮抗剂应在更大规模的人类各种恶性肿瘤的对照研究中进行治疗试验。
